$1.75
0.57% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Fortress Biotech, Inc. Stock price

$1.75
+0.25 16.67% 1M
+0.18 11.47% 6M
-0.28 13.58% YTD
-0.20 10.26% 1Y
-11.57 86.87% 3Y
-37.25 95.51% 5Y
-44.60 96.22% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.01 0.57%
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Key metrics

Market capitalization $51.75m
Enterprise Value $44.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.78
P/S ratio (TTM) P/S ratio 0.90
P/B ratio (TTM) P/B ratio 2.32
Revenue growth (TTM) Revenue growth -32.11%
Revenue (TTM) Revenue $57.78m
EBIT (operating result TTM) EBIT $-96.90m
Free Cash Flow (TTM) Free Cash Flow $-74.37m
Cash position $91.34m
EPS (TTM) EPS $-2.32
P/E forward negative
P/S forward 0.60
EV/Sales forward 0.52
Short interest 15.80%
Show more

Is Fortress Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Fortress Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Fortress Biotech, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Fortress Biotech, Inc. forecast:

Buy
100%

Financial data from Fortress Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
58 58
32% 32%
100%
- Direct Costs 24 24
15% 15%
42%
34 34
41% 41%
58%
- Selling and Administrative Expenses 87 87
15% 15%
151%
- Research and Development Expense 36 36
61% 61%
62%
-90 -90
19% 19%
-155%
- Depreciation and Amortization 7.22 7.22
14% 14%
12%
EBIT (Operating Income) EBIT -97 -97
17% 17%
-168%
Net Profit -41 -41
25% 25%
-71%

In millions USD.

Don't miss a Thing! We will send you all news about Fortress Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fortress Biotech, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of Septemb...
Neutral
GlobeNewsWire
6 days ago
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Confer...
Neutral
GlobeNewsWire
7 days ago
UNLOXCYT™  (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
More Fortress Biotech, Inc. News

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company was founded on June 28, 2006 and is headquartered in New York, NY.

Head office United States
CEO Lindsay Rosenwald
Employees 101
Founded 2006
Website www.fortressbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today